Flerie ABFRA:1NP1 +0.59%27 ROE % is -7.02% as of Mar. 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 1,251 Biotechnology companies, Flerie AB ranks better than 65.63% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Flerie AB's annualized net income for the quarter that ended in Mar. 2026 was €-22.84 Mil. Flerie AB's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €325.52 Mil. Therefore, Flerie AB's annualized ROE % for the quarter that ended in Mar. 2026 was -7.02%.
The historical rank and industry rank for Flerie AB's ROE % or its related term are showing as below:
FRA:1NP1'
s ROE % Range Over the Past 10 Years
Min: -102.66 Med: -43.96 Max: -5.87
Current: -14.91
During the past 12 years, Flerie AB's highest ROE % was -5.87%. The lowest was -102.66%. And the median was -43.96%.
FRA:1NP1's ROE % is ranked better than 65.63% of 1251
companies
in the Biotechnology industry
Industry Median: -38.11
vs FRA:1NP1: -14.91
Flerie AB (FRA:1NP1) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Flerie AB ROE % Related Terms
Flerie AB ROE % Historical Data
* Premium members only.
The historical data trend for Flerie AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Flerie AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flerie AB ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Flerie AB's ROE % distribution charts can be found below:
* The bar in red indicates where Flerie AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Flerie AB (FRA:1NP1) has a ROE % of -7.02% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Flerie AB and its competitors. According to the industry distribution chart, Flerie AB ranks #430 out of 1251 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Flerie AB's ROE % too high?
Flerie AB's current ROE % is -7.02%. Based on the distribution chart, Flerie AB ranks #430 out of 1251 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Flerie AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Flerie AB ranks #430 out of 1251 companies for ROE %. This puts Flerie AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Flerie AB and its competitors. Flerie AB's current ROE % is -7.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current ROE % of -7.02%. The current ROE % is -7.02%. Flerie AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current ROE % is -7.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
27GF Score
Get the complete analysis for FRA:1NP1
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1NP1 has been successfully added to your 
